Aspira Pathlab & Diagnostics Limited

BSE: ASPIRA540788ISIN INE500C01017

Healthcare
Healthcare Service Provider

Share price

₹140.35+2.80 (+2.04%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹149.99
52W low: ₹49.00
Off 52W high: -6.43%
1M return: +12.19%
3M return: +26.16%
6M return: +122.42%
1Y return: +132.68%
20D avg volume: 1,324
50 DMA: ₹114.05
200 DMA: ₹91.96

Key ratios Consolidated

Market cap: ₹144.46 Cr
Current price: ₹140.35
52W high / low: ₹149.99 / ₹49.00
Face value: ₹10.00
P/E: 0.00
P/B: —
EPS (TTM): ₹0.00
Book value / share: —
ROE: —
ROCE: 15.70%
Operating margin: —
Net margin: —
Debt / equity: 0.10
Net debt: ₹-0.54 Cr
Interest cover: 6.77
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 35.2 days

Financials

Metric	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	5.25	5.78	5.41	6.18	4.64	—
	0.11	0.13	0.09	0.08	0.09	—
	5.36	5.91	5.50	6.25	4.73	—
	4.89	5.18	5.12	5.26	4.75	—
	0.90	0.87	0.85	1.10	0.88	—
	0.00	0.00	—	—	—	—
	1.89	1.94	1.97	1.75	1.66	—
	0.09	0.09	0.09	0.08	0.08	—
	0.37	0.37	0.39	0.36	0.38	—
	1.64	1.91	1.60	1.71	1.49	—
	0.47	0.72	0.38	0.99	-0.02	—
	0.00	-0.04	-0.07	0.00	0.00	—
	0.47	0.68	0.31	0.99	-0.02	—
	0.00	0.00	0.00	0.00	0.00	—
	0.42	0.68	0.31	0.99	0.05	—
	0.41	0.66	0.30	0.96	0.05	—
Key metrics
	0.93	1.14	0.79	1.43	0.44	—
	17.70%	19.70%	14.60%	23.10%	9.50%	—
	8.00%	11.80%	5.70%	16.00%	1.10%	—
	—	5.10%	—	—	—	—
	13.10%	—	—	—	—	—
	740.00%	—	—	—	—	—

Metric	TTM	FY25	FY24
Income statement
	22.62	22.00	—
	0.41	0.39	—
	23.02	22.39	—
	20.45	20.32	—
	3.72	3.70	—
	—	0.00	—
	7.55	7.33	—
	0.35	0.35	—
	1.49	1.49	—
	6.86	7.45	—
	2.56	2.07	—
	-0.11	-0.05	—
	2.45	2.02	—
	0.00	0.00	—
	2.40	2.02	—
	2.33	1.97	—
Key metrics
	4.29	3.86	—
	18.97%	17.50%	—
	10.61%	9.20%	—
	—	15.70%	—
	—	1.49	—
	—	0.91	—
	—	0.10	—
	—	-0.54	—
	—	35.2	—
Balance sheet
	—	17.46	—
	—	5.36	—
	—	1.75	—
	—	2.35	—
	—	0.51	—
	—	0.15	—
	—	3.86	—
	—	0.74	—
	—	2.37	—
	—	1.21	—
	—	0.00	—
	—	1.21	—
	—	12.17	—
Cash flow
	—	1.83	—
	—	0.12	—
	—	-0.99	—
	—	0.34	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	6.17	6.52	5.12	8.09	5.25	5.78	5.41	6.18	4.64	—
	0.12	0.14	0.13	0.14	0.11	0.13	0.09	0.08	0.09	—
	6.29	6.66	5.25	8.23	5.36	5.91	5.50	6.25	4.73	—
	6.33	7.35	6.81	6.40	4.89	5.18	5.12	5.26	4.75	—
	0.88	1.22	1.12	1.28	0.90	0.87	0.85	1.10	0.88	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	2.49	2.29	2.45	2.15	1.89	1.94	1.97	1.75	1.66	—
	0.09	0.10	0.10	0.10	0.09	0.09	0.09	0.08	0.08	—
	0.41	0.40	0.38	0.40	0.37	0.37	0.39	0.36	0.38	—
	2.45	3.35	2.76	2.47	1.64	1.91	1.60	1.71	1.49	—
	-0.04	-0.69	-1.56	1.84	0.47	0.72	0.38	0.99	-0.02	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	-0.04	-0.69	-1.56	1.84	0.47	0.72	0.38	0.99	-0.02	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	-0.04	-0.69	-1.56	1.84	0.47	0.72	0.38	0.99	-0.02	—
	-0.04	-0.67	-1.52	1.78	0.46	0.70	0.37	0.96	-0.02	—
Key metrics
	0.46	-0.19	-1.08	2.34	0.93	1.18	0.86	1.43	0.44	—
	7.50%	-2.90%	-21.10%	28.90%	17.70%	20.40%	15.90%	23.10%	9.50%	—
	-0.60%	-10.60%	-30.50%	22.70%	9.00%	12.50%	7.00%	16.00%	-0.40%	—
	—	-3.80%	—	11.20%	—	5.40%	—	—	—	—
	17.50%	12.80%	-5.40%	30.90%	13.10%	—	—	—	—	—
	-108.50%	-195.80%	-510.50%	85.90%	2,450.00%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	25.90	24.98	22.00	—
	0.53	0.52	0.39	—
	26.43	25.50	22.39	—
	26.89	25.45	20.32	—
	4.50	4.52	3.70	—
	0.00	0.00	0.00	—
	9.38	8.78	7.33	—
	0.39	0.39	0.35	—
	1.59	1.54	1.49	—
	11.03	10.22	7.45	—
	-0.45	0.05	2.07	—
	0.00	0.00	0.00	—
	-0.45	0.05	2.07	—
	0.00	0.00	0.00	—
	-0.45	0.05	2.07	—
	-0.45	0.05	2.01	—
Key metrics
	1.53	1.98	3.91	—
	5.91%	7.90%	17.80%	—
	-1.74%	0.20%	9.40%	—
	—	2.90%	16.00%	—
	14.50%	13.50%	—	—
	-117.58%	-97.60%	—	—
	—	0.75	1.54	—
	—	29.00	0.91	—
	—	0.11	0.10	—
	—	0.09	-0.54	—
	—	18.8	35.2	—
Balance sheet
	—	18.51	17.51	—
	—	4.59	5.36	—
	—	1.26	1.75	—
	—	1.73	2.35	—
	—	0.70	0.51	—
	—	0.21	0.15	—
	—	3.88	3.86	—
	—	1.14	0.74	—
	—	3.11	2.37	—
	—	1.35	1.21	—
	—	0.00	0.00	—
	—	1.35	1.21	—
	—	12.23	12.22	—
Cash flow
	—	1.45	1.88	—
	—	-0.80	0.07	—
	—	-1.14	-0.99	—
	—	0.70	0.34	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +14.50%
Profit YoY (TTM): -117.58%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 46.65%

Quarter	September 2026	June 2026
Promoter %	46.65%	46.58%

Holder	Type	Holding	Previous	Change
ARVIND KARSANDAS BHANUSHALI	Promoter	13.79%	13.79%	0.00%
DEEPALI ARVIND BHANUSHALI	Promoter	9.43%	9.43%	0.00%
ADITYA AGRAWAL	Public	7.39%	7.39%	0.00%
JAY ARVIND BHANUSHALI	Promoter	7.30%	7.23%	+0.07%
NIKUNJ VELJI MANGE	Promoter	7.11%	7.11%	0.00%
RAJ ARVIND BHANUSHALI	Promoter Group	6.97%	6.97%	0.00%
RAJESH PREMJI BHANUSHALI	Public	5.52%	5.52%	0.00%
PANKAJ JASHWANT SHAH	Public	4.86%	4.86%	0.00%
POOJA RAJESH BHANUSHALI	Public	3.60%	3.60%	0.00%
MANAS MODI	Public	3.36%	3.36%	0.00%
AMIT MODI	Public	2.92%	2.92%	0.00%
PUSPAHAS AGRAWAL	Public	2.80%	2.80%	0.00%
RAM AWTAR RAMSISARIA	Public	2.40%	2.40%	0.00%
MANOJ RAMSISARIA	Public	1.99%	1.99%	0.00%
SHRADHA RAMSISARIA	Public	1.47%	1.47%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Dr. Lal Pathlabs Limited	34,056	2,028.95	57.92	25.70%	+16.71% TTM	+8.93% TTM	+28.73%
Vijaya Diagnostic Centre Limited	14,676	1,424.85	72.05	19.20%	+24.48% TTM	+33.96% TTM	+39.02%
Metropolis Healthcare Limited	12,075	582.05	53.57	15.70%	+19.84% TTM	+41.90% TTM	+14.58%
Thyrocare Technologies Limited	7,883	495.25	55.01	33.60%	+21.99% TTM	+13.16% TTM	+9.41%
Nephrocare Health Services Limited	6,242	620.75	48.72	13.70%	—	—	—
SURAKSHA DIAGNOSTIC LIMITED	1,735	333.10	49.46	14.70%	+23.32% TTM	+7.94% TTM	+2.54%
Krsnaa Diagnostics Limited	1,566	482.90	15.97	10.60%	+15.90% TTM	+16.02% TTM	-37.25%
3B BlackBio Dx Limited	1,142	1,330.25	20.29	22.60%	+54.30% TTM	+14.75% TTM	-1.52%
HEALTH X PLATFORM LIMITED	863	271.20	-33.11	—	+28.85% TTM	+82.45% TTM	-8.73%
ONE GLOBAL SERVICE PROVIDER LIMITED S	861	440.70	11.65	65.70%	+161.55% TTM	+178.28% TTM	+21.17%
Gaudium IVF and Women Health Limited	779	107.05	—	23.10%	—	—	—
Aspira Pathlab & Diagnostics Limited S	144	140.35	-318.98	2.90%	+14.50% TTM	-117.58% TTM	+132.68%
Choksi Laboratories Ltd. S	142	203.90	65.77	12.30%	+10.74% TTM	+44.00% TTM	+38.05%
STAR IMAGING AND PATH LAB LIMITED	120	68.90	—	22.60%	—	—	-51.78%
MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED S	86	57.00	—	11.20%	—	—	—
Sharma East India Hospitals And Res S	34	87.05	24.11	14.20%	+14.13% TTM	-9.85% TTM	-38.28%
BANDARAM PHARMA PACKTECH LIMITED	34	19.03	25.81	4.70%	+114.59% TTM	+454.17% TTM	-22.14%
N.G.Industries Ltd. S	34	100.00	17.39	6.30%	+2.18% TTM	-74.06% TTM	-23.28%
Deccan Health Care Limited	29	12.00	11.40	3.20%	-0.37% TTM	+145.63% TTM	-29.41%
Chennai Meenakshi Multispeciality Hospital Ltd. S	27	36.78	-32.26	-2.80%	+0.08% TTM	+6.59% TTM	-29.27%
SAMSRITA LABS LIMITED	27	11.93	-3.33	-73.40%	—	—	-43.35%
Tejnaksh Healthcare Limited	26	12.83	21.19	5.90%	-12.97% TTM	-33.15% TTM	-27.02%
Transgene Biotek Ltd.	17	2.57	-12.11	-0.50%	-14.81% TTM	-23.85% TTM	-28.21%
Dolphin Medical Services Ltd. S	11	7.11	59.25	0.60%	-1.25% TTM	+700.00% TTM	+246.83%
Looks Health Services Limited S	11	10.08	504.00	0.20%	-41.89% TTM	-57.14% TTM	+101.20%

Filings & corporate actions

Recent announcements

Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Un-audited Financial ....31 Oct 2026 · Board Meeting / Board Meeting
Compliance Certificate under reg 74(5) of SEBI (DP) regulation, 2018 for the quarter ended September 30, 2026.8 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali1 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali28 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosure of Voting Results of 53rd Annual General Meeting along with the Scrutinizer Report25 Sep 2026 · AGM/EGM / AGM
Please find attached summary of proceeding /outcome of the 53rd Annual General Meeting of the Company held on Friday,25th September,202625 Sep 2026 · AGM/EGM / AGM
Closure of Trading Window for quarter ended September 30,202623 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali16 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Enclosed herewith Constitution of Right Issue Committee for proposed right issue12 Sep 2026 · Company Update / General
Intimation under Regulation 30 (LODR) -Raising of Funds12 Sep 2026 · Company Update / Raising of Funds
The Board of Directors of the Company in its meeting held on 12th September, 2026 have considered and approved the following matters; 1) To raise Fund for an amount not exceeding Rs. 65,00,00,000/- ....12 Sep 2026 · Board Meeting / Outcome of Board Meeting
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali12 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/09/2026 ,inter alia, to consider and approve To consider approve ....7 Sep 2026 · Board Meeting / Board Meeting
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali5 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali3 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Pursuant to Regulation 36 (1)(b) of SEBI (LODR)2015, The Company has dispatched letter containing weblink of Annual Report for Financial year 2025-261 Sep 2026 · Company Update / General
Newspaper Publication Post Dispatch of 53rd AGM Notice & Annual Report for the Financial Year 2025-261 Sep 2026 · Company Update / Newspaper Publication
Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the Notice of ....31 Aug 2026 · Others / Reg. 34 (1) Annual Report
Intimation of Notice of 53rd Annual General Meeting for the Financial Year 2025-2631 Aug 2026 · AGM/EGM / AGM
With reference to subject matter please find the attached Documents31 Aug 2026 · Corp. Action / Book Closure
Newspaper Advertisement - Information Regarding 53rd (Fifty -Three) Annual General Meeting of the company28 Aug 2026 · Company Update / Newspaper Publication
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali28 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Newspaper Publication for the Financial Result as on 30 June 202613 Aug 2026 · Company Update / Newspaper Publication
1. Board approved the appointment of Mr. Vaibhav Odhekar as Additional Executive Director with immediate Effect. 2. Board Approved the regularization of Mr. Vaibhav Odhekar as Executive ....12 Aug 2026 · Company Update / Change in Management
Unaudited Standalone Financial Results for quarter ended 30 June 202612 Aug 2026 · Result / Financial Results
Outcome of Board Meeting held on 12th August 202612 Aug 2026 · Board Meeting / Outcome of Board Meeting
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1.Unaudited Financial ....6 Aug 2026 · Board Meeting / Board Meeting
Enclosed herewith Resignation of M/s Vishal J Bhanushali and Associated with effect from 13th August 20263 Aug 2026 · Company Update / General
Enclosed herewith Resignation of Mr. Pankaj Jashwant Shah from post of Managing Director and Chief Executive Officer with effect from 03.08.20263 Aug 2026 · Company Update / Resignation of Chief Executive Officer (CEO)
Enclosed herewith Resignation of Mr. Pankaj Jashwant Shah from post of Managing Director cum Chief Executive Officer with effect from 03.08.20263 Aug 2026 · Company Update / Resignation of Managing Director
Enclosed herewith Resignation of Pankaj jashwant Shah (DIN:02836324)3 Aug 2026 · Company Update / Resignation of Director
Mr. Vaibhav Odhekar has resigned from Company as an Additional Executive Director with effect from close of business hours 25.07.202625 Jul 2026 · Company Update / Resignation of Director
Resignation of Mr. Vaibhav Odhekar as an Additional Executive Director from Company with effect from close of business hours on 25.07.202625 Jul 2026 · Company Update / Change in Directorate
Compliance Certificate in accordance with regulation 74(5) of SEBI (DP) regulation 2018 for quarter ended 30th June 202613 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of closure of Trading window for quarter ended 30.06.202624 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of Classification of Mr. Nikunj Mange and Mr. Jay Arvind Bhanushali as Promoters of the Company Pursuant to Completion of Open Offer11 Jun 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shraddha Bhanushali & PACs11 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deepali Arvind Bhanushali & PACs11 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raj Arvind Bhanushali & PACs11 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali & PACs10 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Board meetings

6 Nov 2026 Board Meeting - Financial Results
12 Aug 2026 Board Meeting - Financial Results